Sugi Predict

Sugi Predict / Compounds / SCHEMBL937066

SCHEMBL937066

SCHEMBL937066

FC(F)(F)Oc1ccc(-c2ccc3nnc(C(F)(F)F)n3c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ SCN5A Q14524 20/20 1.00
▸ SCN1A P35498 1/20 1.00
▸ SCN2A Q99250 1/20 1.00
▸ CYP1A2 P05177 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL936728 0.89 SCN5A (0.80) SCN5ASCN1ASCN2ACYP1A2
SCHEMBL15929739 0.89 SCN5A (0.80) SCN5ASCN1ASCN2ACYP1A2
SCHEMBL937441 0.89 SCN5A (0.80) SCN5ASCN1ASCN2ACYP1A2
SCHEMBL937431 0.86 SCN5A (0.76) SCN5ASCN1ASCN2ACYP1A2
SCHEMBL936687 0.85 SCN5A (1.00) SCN5ASCN1ASCN2ACYP1A2
SCHEMBL937046 0.85 SCN5A (0.74) SCN5ASCN1ASCN2ACYP1A2
SCHEMBL936547 0.85 SCN5A (0.74) SCN5ASCN1ASCN2ACYP1A2
SCHEMBL933926 0.85 SCN5A (0.74) SCN5ASCN1ASCN2ACYP1A2
SCHEMBL937289 0.85 SCN5A (0.74) SCN5ASCN1ASCN2ACYP1A2
SCHEMBL938181 0.84 SCN5A (0.72) SCN5ASCN1ASCN2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2464645-B1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES INC (US) 2017-07-05 — — EP claimed
US-8952034-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2015-02-10 — — US claimed
US-8754103-B2 — — 2014-06-17 — — US claimed
CN-116406355-B P38 alpha mitogen-activated protein kinase inhibitors GEN1E生命科学公司 2026-05-15 — — CN disclosed
CN-117120422-B Substituted naphthyl P38 alpha mitogen-activated protein kinase inhibitors GEN1E生命科学公司 2026-05-12 — — CN disclosed
US-12595243-B2 Modulators of extracellular signal-regulated kinase GEN1E LIFESCIENCES INC. (US) 2026-04-07 — — US disclosed
US-20250376475-A1 ION CHANNEL MODULATORS PRAXIS PREC MEDICINES INC (US) 2025-12-11 — — US disclosed
US-20250353826-A1 INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE GEN1E LIFESCIENCES INC (US) 2025-11-20 — — US disclosed
US-12404259-B2 Inhibitors of extracellular signal-regulated kinase GEN1E LIFESCIENCES INC. (US) 2025-09-02 — — US disclosed
US-20250243154-A1 CRYSTALLINE 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE DI-HYDROCHLORIDE DI-HYDRATE GEN1E LIFESCIENCES INC. 2025-07-31 — — US disclosed
US-20250136571-A1 MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE GEN1E LIFESCIENCES INC. 2025-05-01 — — US disclosed
US-20140221286-A1 SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION GILEAD SCIENCES, INC. 2014-08-07 — — US disclosed
EP-2758053-A1 SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION Gilead Sciences, Inc. (US) 2014-07-30 — — EP disclosed
US-8754103-B2 — — 2014-06-17 — — US disclosed
US-8754103-B2 — — 2014-06-17 — — US disclosed
WO-2013043925-A1 SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION GILEAD SCIENCES, INC. (US) 2013-03-28 — — WO disclosed
WO-2011014462-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2011-02-03 — — WO disclosed
US-20110021521-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2011-01-27 — — US disclosed
US-20110021521-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2011-01-27 — — US disclosed
US-20110021521-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2011-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221286-A1 SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION IAPP, SCNN1B, GLP1R SCN5A 24/4885SCN1A 13/4885SCN2A 18/4885
US-20250353826-A1 INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE MAP3K20, MAP3K6, MAP3K19 SCN5A 4388/4885SCN1A 4453/4885SCN2A 4429/4885
US-12404259-B2 Inhibitors of extracellular signal-regulated kinase MAP3K20, MAP3K6, MAP3K19 SCN5A 4388/4885SCN1A 4453/4885SCN2A 4429/4885
US-20250136571-A1 MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE MAP3K20, MAP3K6, CDC42BPG SCN5A 4444/4885SCN1A 4450/4885SCN2A 4226/4885
US-20250243154-A1 CRYSTALLINE 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE DI-HYDROCHLORIDE DI-HYDRATE REN, PKD1, DSP SCN5A 10/4885SCN1A 43/4885SCN2A 70/4885
US-20110021521-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, KCNH2, KCNA3 SCN5A 52/4885SCN1A 55/4885SCN2A 72/4885
US-20250376475-A1 ION CHANNEL MODULATORS SCN1A, SCN3A, SCN2A SCN5A 5/4885SCN1A 1/4885SCN2A 3/4885
US-12595243-B2 Modulators of extracellular signal-regulated kinase CDC42BPG, GRK3, ERBB2 SCN5A 2071/4885SCN1A 1776/4885SCN2A 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.